ReviewFrontiers in pharmacology2026
Cervical human papillomavirus: the therapeutic target of botanical drugs.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Microbiome-Mitochondria-Extracellular Vesicle Axis in HPV Persistence and Cervical Carcinogenesis.Genes · 2026Review
- Targeting the HPV E6-p53 degradation axis via computational andFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent cervical human papillomavirus (HPV) infection is the key biological event underlying high-grade squamous intraepithelial lesions, cervical cancer development, and recurrence risk. Botanical drugs and their bioactive metabolites have therefore attracted interest as potential adjunctive interventions, particularly because they can modulate multiple biological pathways relevant to viral persistence and clearance. This review critically synthesizes the botanical drugs and their metabolites evaluated in cervical HPV-related studies, organizing the available evidence around experimentally interpretable therapeutic outputs. The reviewed literature indicates that specific botanical drugs are associated with the suppression of HPV oncogene expression, the disruption of viral DNA maintenance, and the modulation of critical host responses. However, the current evidence remains heterogeneous and is fundamentally limited by incomplete phytochemical characterization, variable experimental model relevance, insufficient pharmacokinetic data, and an overreliance on simplified preclinical systems. Overall, current findings support the pharmacological relevance of selected botanical drugs in persistence-related cervical HPV biology, but they do not yet establish consistent clinical efficacy. Future research should prioritize standardized botanical formulations, genotype-stratified study designs, persistence-relevant biomarkers, and durable virological and lesion-related outcomes to improve translational value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.